MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia

• Published in: International journal of hematology Vol. 78; no. 5; pp. 439 - 442
• Main Authors: TSUJIOKA, Takayuki, WADA, Hideho, YAMAMORI, Shunji, OTSUKI, Takemi, SUEMORI, Sinichiro, KONDO, Toshinori, NAKANISHI, Hidekazu, SUETSUGU, Yoshimasa, MIKAMI, Makoto, SUGIHARA, Takashi
• Format: Journal Article
• Language: English
• Published: Tokyo Springer 01.12.2003; Springer Nature B.V
• Subjects: Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chromosomes, Human, Pair 1 - genetics; Chromosomes, Human, Pair 1 - ultrastructure; Chromosomes, Human, Pair 11 - genetics; Chromosomes, Human, Pair 11 - ultrastructure; Cytarabine - administration & dosage; Daunorubicin - administration & dosage; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Etoposide - administration & dosage; Etoposide - adverse effects; Fatal Outcome; Hematologic and hematopoietic diseases; Humans; Idarubicin - administration & dosage; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Mitoxantrone - administration & dosage; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins - antagonists & inhibitors; Neoplasms, Second Primary - chemically induced; Neoplasms, Second Primary - genetics; Oncogene Proteins, Fusion - genetics; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - chemically induced; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin - administration & dosage; Chromosomal aberration; Antineoplastic agent; Human; Promyelocytic leukemia; DNA topoisomerase (ATP-hydrolysing); Enzyme; Toxicity; Acute; Enzyme inhibitor; Etoposide; Malignant hemopathy; Precursor B lymphoblastic leukemia; Podophyllotoxine derivatives; Case study; Chemotherapy; Isomerases; Treatment; Abnormal chromosome A1; Abnormal chromosome; Acute lymphocytic leukemia; Abnormal chromosome C11; Antimitotic; Hybrid gene; Chromosome translocation
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/BF02983817

We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion. This case suggests that careful monitoring for MLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.